Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH)’s stock price was down 3.5% on Monday . The company traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares traded hands during trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Stock Down 3.5 %
The company has a quick ratio of 11.02, a current ratio of 11.93 and a debt-to-equity ratio of 2.69. The company has a market cap of C$2.15 billion and a P/E ratio of -11.32. The business has a 50-day simple moving average of C$16.76.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- How to Invest in Small Cap Stocks
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How to Start Investing in Real Estate
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Buy P&G Now, Before It Sets A New All-Time High
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
